German Doctors Hits 4th Qtr Drug Sales In Budgets Row
German Doctors Hit 4th Qtr Drug Sales In Budgets Row
A fresh cloud has appeared on the German drug market, as doctors reacted with unexpected severity to the new debate over drug budgets. Drugmakers report that November and December sales and profits forecasts have been revised downwards over 20%. Market growth of 7.5% through most of 1996 may be wiped out in the last two months as doctors cut back on prescribing.
Industry sources say 1997 prospects are beginning to look decidedly bleak, with forecasts ranging from stagnation to a decline of 10% in drug sales next year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze